Topical use of hormone injection in the treatment of ocular myasthenia gravis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024285

Enrollment

Unknown

Registered

2019-07-05

Start date

2019-08-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular myasthenia gravis

Interventions

Local injection of hormone:Local injection of hormone

Systemic use of hormone group:Systemic use of hormone

Local injection + Systemic use of hormone group:Local injection + Systemic use of hormone

Eligibility

Sex/Gender

All

Age

4 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with ocular myasthenia gravis who visited our hospital from August 2019 to August 2021, diagnosed according to typical symptoms and signs and neostigmine test.

Exclusion criteria

Exclusion criteria: Those with systemic symptoms (with hypothyroidism below the neck), who are not supportive of the treatment plan, are unable to complete the follow-up on time.

Design outcomes

Primary

Measure	Time frame
Squint degree;	—

Secondary

Measure	Time frame
vision;intraocular pressure;	—

Countries

China

Contacts

Public ContactMinghua Shi

Wuhan Aier Eye Hospital (Hanyang)

13995559689@163.com+86 13995559689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026